Phase 2 Study of Poziotinib in Participants With NSCLC Having EGFR or HER2 Exon 20 Insertion Mutation
Clinical trial NCT03318939 · TERMINATED
Trial details
- NCT number
- NCT03318939
- Sponsor
- Spectrum Pharmaceuticals, Inc
- Status
- TERMINATED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2017-10-11
- Primary completion
- 2023-04-03
- Enrollment
- 648
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.